Value proposition: cost and opportunityGiven the relatively low share count and the stunningly but persistently low share price, one can buy .001 of this whole company (one tenth of one percent, or 58,000 shares) for about $94,000 Cdn.
That is a big financial commitment and a huge share of most investors' high risk portfolio allocation.
But look at the intellectual property and market opportunity that comes with that big of a commitment. Reflect for a few moments on owning that large a holding in a company with these clinical and market opportunities.
Personally, I am well below that level of commitment. But I have increased my holdings by over 50% over the last four months. I have been lowering my ACB the whole time at the current prices.
Finally, the downside risk is minimal from here in my view, if you have a reasonable time horizon. The accumlated tax loss of the company is $550 mil IIRC, ignoring the patents and trials underway.
But I must acknowledge I have been following this reasoning for a very long time, and am still somewhat underwater. DYODD.